 |
|
|
| |
8 weeks of grazoprevir plus elbasvir for acute hepatitis C virus genotype 1 or 4 infection - the DAHHS 2 study - a single-arm, prospective, open-label, multicenter phase 3b trial
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
Anne Boerekamps, Anja De Weggheleire, Guido E. van den Berk, Fanny N. Lauw, Mark A.A. Claassen, Dirk Posthouwer, Wouter F. Bierman, Sebastiaan J. Hullegie, Eric Florence, Andre Boonstra, Ton Dofferhoff, Joop E. Arends, Bart J.A. Rijnders
|
| |
|
|
|
|
|
